SRC as a Prognostic and Immunomodulatory Biomarker in Acute Myeloid Leukemia: A Multi-Omics Study
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27093734 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Jirui Zhong und 3 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510405, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Biomarkers, Tumor, src-Family Kinases, Immunomodulation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, the "Guben" Engineering First-Class Discipline Capacity Improvement Project of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine.
Abstract (Originalsprache)
The bone marrow tumor microenvironment (TME) is critical for acute myeloid leukemia (AML) progression, immune evasion, and treatment resistance. SRC, a non-receptor tyrosine kinase involved in multiple oncogenic pathways, has not been systematically characterized in AML in relation to prognosis and immune regulation. We integrated bulk transcriptomic and single-cell RNA-sequencing datasets from TCGA, BeatAML, and GEO. Immune-related targets were identified using xCell-based immune scoring and weighted gene co-expression network analysis (WGCNA), followed by protein–protein interaction analysis and multi-algorithm machine-learning screening. We then evaluated SRC expression patterns, prognostic associations, immune microenvironment features, predicted drug sensitivity, single-cell differentiation dynamics, intercellular communication, and in silico virtual knockout perturbation (scTenifoldKnk). SRC emerged as the most robust hub gene after integration of WGCNA, PPI analysis, machine-learning feature selection, and survival screening. SRC was significantly upregulated in AML compared with normal controls and was independently associated with poor overall survival (HR = 1.231, p = 0.037). High SRC expression was linked to adverse ELN/FAB features, increased immune checkpoint expression, enrichment of inflammatory and immunoregulatory pathways, and a higher proportion of primitive leukemia-associated cell states. Single-cell analyses further suggested that SRC was enriched in CD34+ progenitor compartments, associated with altered cell–cell communication, and accompanied by distinct mutation and pathway profiles. Drug-response prediction and in silico network perturbation analysis further supported the potential biological and translational relevance of SRC-centered programs. SRC is a prognostically relevant and immune-associated hub linked to AML microenvironment remodeling, and may serve as a candidate biomarker and potential therapeutic target that warrants further experimental validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
- Department of Hematology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
ORCID-Profile: Jirui Zhong
Förderung
- National Natural Science Foundation of China
- the "Guben" Engineering First-Class Discipline Capacity Improvement Project of Guangzhou University of Chinese Medicine
- Guangzhou University of Chinese Medicine
Zitieren
APA
Zhong, J., Liu, X., Gu, X., & Liu, Z. (2026). SRC as a Prognostic and Immunomodulatory Biomarker in Acute Myeloid Leukemia: A Multi-Omics Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27093734
Vancouver
Zhong J, Liu X, Gu X, Liu Z. SRC as a Prognostic and Immunomodulatory Biomarker in Acute Myeloid Leukemia: A Multi-Omics Study. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27093734
BibTeX
@article{Zhong2026,
author = {Zhong, Jirui and Liu, Xikun and Gu, Xuekui and Liu, Zenghui},
title = {SRC as a Prognostic and Immunomodulatory Biomarker in Acute Myeloid Leukemia: A Multi-Omics Study},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27093734}
}
EUVIMED